← Back to Search

Monoclonal Antibodies

Pre-PDT for Visual Acuity

Phase 4
Waitlist Available
Led By John Galic, MD
Research Sponsored by McGill University Health Centre/Research Institute of the McGill University Health Centre
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up one year
Awards & highlights

Study Summary

The purpose of the investigators study is to look at the visual outcomes of Ranibizumab injections in combination with photodynamic therapy for the treatment of neovascular age-related macular degeneration.

Eligible Conditions
  • Visual Acuity
  • Age-Related Macular Degeneration

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~one year
This trial's timeline: 3 weeks for screening, Varies for treatment, and one year for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Mean change from baseline at 6 months in the best corrected visual acuity (VA) score using an early treatment diabetic retinopathy study eye chart at a starting distance of 4 meters.
Secondary outcome measures
To determine the following: 1:Proportion of subjects who loose fewer than 15 letters from baseline visual acuity at 6 months 2: Proportion of subjects with VA of 20/200 or worse 3: Proportion of subjects with VA of 20/40 or better

Trial Design

3Treatment groups
Active Control
Group I: Pre-PDTActive Control1 Intervention
Participants in this group will receive an intraocular Ranibizumab injection one week prior to the first PDT with verteporfin.
Group II: No PDTActive Control1 Intervention
Participants in this group will receive an intraocular Ranibizumab injection with no accompanying PDT with verteporfin.
Group III: Post-PDTActive Control1 Intervention
Participants in this group will receive an intraocular Ranibizumab injection one week post the first PDT with verteporfin.

Find a Location

Who is running the clinical trial?

McGill University Health Centre/Research Institute of the McGill University Health CentreLead Sponsor
444 Previous Clinical Trials
159,368 Total Patients Enrolled
John Galic, MDPrincipal InvestigatorMontreal Retina Institute
John Chen, MDPrincipal InvestigatorMontreal Retina Institute

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.
Recent research and studies
Archives of OphthalmologyJournal
Prevalence of Age-related Macular Degeneration in the United States
“Prevalence of Age-related Macular Degeneration in the United States”. 2004. “Prevalence of Age-related Macular Degeneration in the United States”. Archives of Ophthalmology. American Medical Association (AMA). doi:10.1001/archopht.122.4.564.
The American Journal of PathologyJournal
Intrachoroidal Neovascularization in Transgenic Mice Overexpressing Vascular Endothelial Growth Factor in the Retinal Pigment Epithelium
Schwesinger, Catherine, Charles Yee, Richard M. Rohan, Antonia M. Joussen, Antonio Fernandez, Tobias N. Meyer, Vassiliki Poulaki, et al.. 2001. “Intrachoroidal Neovascularization in Transgenic Mice Overexpressing Vascular Endothelial Growth Factor in the Retinal Pigment Epithelium”. The American Journal of Pathology. Elsevier BV. doi:10.1016/s0002-9440(10)64063-1.
New England Journal of MedicineJournal
Ranibizumab for Neovascular Age-related Macular Degeneration
Rosenfeld, Philip J., David M. Brown, Jeffrey S. Heier, David S. Boyer, Peter K. Kaiser, Carol Y. Chung, and Robert Y. Kim. 2006. “Ranibizumab for Neovascular Age-related Macular Degeneration”. New England Journal of Medicine. Massachusetts Medical Society. doi:10.1056/nejmoa054481.
New England Journal of MedicineJournal
Ranibizumab Versus Verteporfin for Neovascular Age-related Macular Degeneration
Brown, David M., Peter K. Kaiser, Mark Michels, Gisele Soubrane, Jeffrey S. Heier, Robert Y. Kim, Judy P. Sy, and Susan Schneider. 2006. “Ranibizumab Versus Verteporfin for Neovascular Age-related Macular Degeneration”. New England Journal of Medicine. Massachusetts Medical Society. doi:10.1056/nejmoa062655.
All > Age Related Macular Degeneration > Macular Degeneration
~11 spots leftby Apr 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top